These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1078 related items for PubMed ID: 27689725

  • 1. Synthesis, in vitro evaluation and molecular docking studies of novel triazine-triazole derivatives as potential α-glucosidase inhibitors.
    Wang G, Peng Z, Wang J, Li X, Li J.
    Eur J Med Chem; 2017 Jan 05; 125():423-429. PubMed ID: 27689725
    [Abstract] [Full Text] [Related]

  • 2. Synthesis, biological evaluation, and docking studies of novel 5,6-diaryl-1,2,4-triazine thiazole derivatives as a new class of α-glucosidase inhibitors.
    Wang G, Peng Z, Gong Z, Li Y.
    Bioorg Chem; 2018 Aug 05; 78():195-200. PubMed ID: 29587132
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and biological evaluation of novel 1,2,4-triazine derivatives bearing carbazole moiety as potent α-glucosidase inhibitors.
    Wang G, Wang J, He D, Li X, Li J, Peng Z.
    Bioorg Med Chem Lett; 2016 Jun 15; 26(12):2806-2809. PubMed ID: 27177827
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and biological evaluation of novel 2,4,5-triarylimidazole-1,2,3-triazole derivatives via click chemistry as α-glucosidase inhibitors.
    Wang G, Peng Z, Wang J, Li J, Li X.
    Bioorg Med Chem Lett; 2016 Dec 01; 26(23):5719-5723. PubMed ID: 27810241
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro α-glucosidase inhibition, kinetic, and docking studies.
    Asgari MS, Mohammadi-Khanaposhtani M, Kiani M, Ranjbar PR, Zabihi E, Pourbagher R, Rahimi R, Faramarzi MA, Biglar M, Larijani B, Mahdavi M, Hamedifar H, Hajimiri MH.
    Bioorg Chem; 2019 Nov 01; 92():103206. PubMed ID: 31445191
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Design, synthesis, in vitro, and in silico studies of novel diarylimidazole-1,2,3-triazole hybrids as potent α-glucosidase inhibitors.
    Saeedi M, Mohammadi-Khanaposhtani M, Asgari MS, Eghbalnejad N, Imanparast S, Faramarzi MA, Larijani B, Mahdavi M, Akbarzadeh T.
    Bioorg Med Chem; 2019 Dec 01; 27(23):115148. PubMed ID: 31679980
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis, in vitro, and in silico anti-α-glucosidase assays of N-phenylacetamide-1,2,3-triazole-indole-2-carboxamide derivatives as new anti-diabetic agents.
    Sayahi MH, Zareei S, Halimi M, Alikhani M, Moazzam A, Mohammadi-Khanaposhtani M, Mojtabavi S, Faramarzi MA, Rastegar H, Taslimi P, Ibrahim EH, Ghramh HA, Larijani B, Mahdavi M.
    Sci Rep; 2024 Jul 09; 14(1):15791. PubMed ID: 38982268
    [Abstract] [Full Text] [Related]

  • 10. New carbazole linked 1,2,3-triazoles as highly potent non-sugar α-glucosidase inhibitors.
    Iqbal S, Khan MA, Javaid K, Sadiq R, Fazal-Ur-Rehman S, Choudhary MI, Basha FZ.
    Bioorg Chem; 2017 Oct 09; 74():72-81. PubMed ID: 28756277
    [Abstract] [Full Text] [Related]

  • 11. New phenylthiosemicarbazide-phenoxy-1,2,3-triazole-N-phenylacetamides as dual inhibitors against α-glucosidase and PTP-1B for the treatment of type 2 diabetes.
    Ansariashlaghi S, Fakhrioliaei A, Mohammadi-Khanaposhtani M, Noori M, Asadi M, Mojtabavi S, Faramarzi MA, Esfahani EN, Rastegar H, Larijani B, Azizian H, Mahdavi M.
    Arch Pharm (Weinheim); 2024 Jul 09; 357(7):e2300517. PubMed ID: 38593290
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Triazinoindole analogs as potent inhibitors of α-glucosidase: synthesis, biological evaluation and molecular docking studies.
    Rahim F, Ullah K, Ullah H, Wadood A, Taha M, Ur Rehman A, uddin I, Ashraf M, Shaukat A, Rehman W, Hussain S, Khan KM.
    Bioorg Chem; 2015 Feb 09; 58():81-7. PubMed ID: 25528720
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Design, synthesis and docking study of novel tetracyclic oxindole derivatives as α-glucosidase inhibitors.
    Han K, Li Y, Zhang Y, Teng Y, Ma Y, Wang M, Wang R, Xu W, Yao Q, Zhang Y, Qin H, Sun H, Yu P.
    Bioorg Med Chem Lett; 2015 Apr 01; 25(7):1471-5. PubMed ID: 25759031
    [Abstract] [Full Text] [Related]

  • 18. Synthesis, docking and ADMET studies of novel chalcone triazoles for anti-cancer and anti-diabetic activity.
    Chinthala Y, Thakur S, Tirunagari S, Chinde S, Domatti AK, Arigari NK, K V N S S, Alam S, Jonnala KK, Khan F, Tiwari A, Grover P.
    Eur J Med Chem; 2015 Mar 26; 93():564-73. PubMed ID: 25743216
    [Abstract] [Full Text] [Related]

  • 19. Design and synthesis of novel xanthone-triazole derivatives as potential antidiabetic agents: α-Glucosidase inhibition and glucose uptake promotion.
    Ye GJ, Lan T, Huang ZX, Cheng XN, Cai CY, Ding SM, Xie ML, Wang B.
    Eur J Med Chem; 2019 Sep 01; 177():362-373. PubMed ID: 31158750
    [Abstract] [Full Text] [Related]

  • 20. Synthesis, molecular docking and α-glucosidase inhibition of 2-((5,6-diphenyl-1,2,4-triazin-3-yl)thio)-N-arylacetamides.
    Wang G, Li X, Wang J, Xie Z, Li L, Chen M, Chen S, Peng Y.
    Bioorg Med Chem Lett; 2017 Mar 01; 27(5):1115-1118. PubMed ID: 28189421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.